Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 7:24 PM
Ignite Modification Date:
2025-12-25 @ 5:03 PM
NCT ID:
NCT02272803
Group ID:
EG000
Title:
Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)
Description:
Lenalidomide
25 mg taken orally once daily, Days 1 - 21 of each cycle
Dexamethasone
Administered on Days 1, 8, 15, and 22 of each cycle:
On weeks when elotuzumab is administered:
* 28 mg taken orally (3 - 24 hours prior to start of elotuzumab infusion) AND
* 8 mg IV (at least 45 minutes prior to elotuzumab administration)
On weeks when elotuzumab is NOT administered:
\- 40 mg taken orally
Elotuzumab (BMS-901608)
* Cycle 1 - 2: 10 mg/kg IV, Days 1, 8, 15, 22
* Cycle 3 - 18: 10 mg/kg IV, Days 1 and 15
* Cycle 19 and beyond: 20 mg/kg IV, Day 1
Deaths Number Affected:
2
Deaths Number At Risk:
None
Serious Number Affected:
26
Serious Number At Risk:
40
Other Number Affected:
39
Other Number At Risk:
40
Study:
NCT02272803
Results Section:
NCT02272803
Adverse Events Module:
NCT02272803